Xencor Collaborates with Genentech for Novel Interleukin-15 Bispecific Antibodies

By Jasmine Kalsi & Michelle Liu

Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)

Published: 9 Feb-2019

DOI: 10.3833/pdr.v2019.i2.2405     ISSN: 1756-7874

Section: Research & Development



Just weeks after regaining rights to a bispecific antibody from Novartis, Xencor has entered into a research collaboration and license agreement with Genentech to develop and commercialise interleukin-15 (IL-15) therapeutics...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details